% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Walter:144745,
author = {V. Walter$^*$ and D. Boakye$^*$ and J. Weberpals$^*$ and L.
Jansen$^*$ and W. E. Haefeli and U. M. Martens and P. Knebel
and J. Chang-Claude$^*$ and M. Hoffmeister$^*$ and H.
Brenner$^*$},
title = {{D}ecreasing {U}se of {C}hemotherapy in {O}lder {P}atients
{W}ith {S}tage {III} {C}olon {C}ancer {I}rrespective of
{C}omorbidities.},
journal = {Journal of the National Comprehensive Cancer Network},
volume = {17},
number = {9},
issn = {1540-1413},
address = {Cold Spring Harbor, NY},
publisher = {Harborside Press},
reportid = {DKFZ-2019-02177},
pages = {1089 - 1099},
year = {2019},
abstract = {Chemotherapy underuse in elderly patients (aged ≥75
years) with colon cancer has been reported in previous
studies. However, these studies were mostly registry-based
and limited in their potential to consider underlying
reasons of such undertreatment. This study aimed to evaluate
patient and hospital determinants of chemotherapeutic
treatment in patients with stage III colon cancer, with a
particular focus on age and underlying reasons for
nontreatment of elderly patients.A total of 629 patients
with stage III colon cancer who were diagnosed in 2003
through 2012 and recruited into a population-based study in
the Rhine-Neckar region of Germany were included.
Information on sociodemographic and lifestyle factors,
comorbidities, and treatment was collected from patient
interviews and physicians. Patient (with an emphasis on age)
and hospital factors were evaluated for their associations
with administration of adjuvant chemotherapy overall and of
oxaliplatin specifically using multivariable logistic
regression.Administration of chemotherapy decreased from
$94\%$ in patients aged 30 to 64 years to $51\%$ in those
aged ≥75 years. A very strong decline in chemotherapy use
with age persisted even after comprehensive adjustment for
multiple patient factors-including comorbidities-and
hospital factors and was also seen among patients without
any major comorbidities. Between 2005 and 2008, and 2009 and
2012, chemotherapy administration in patients aged ≥75
years decreased from $60\%$ to $41\%.$ Among chemotherapy
recipients, old age was also strongly associated with higher
odds of nonadministration of oxaliplatin. The 2 most
commonly reported reasons for chemotherapy nonreceipt among
the study population were patient refusal $(30\%)$ and old
age $(24\%).Age$ was the strongest predictor of chemotherapy
underuse, irrespective of comorbidities and even in patients
without comorbidities. Such underuse due just to older age
in otherwise healthy patients deserves increased attention
in clinical practice to ensure that elderly patients also
get the best possible care. Patients' refusal as the most
frequent reason for chemotherapy nonreceipt also warrants
further investigation to exclude misinformation as
underlying cause.},
cin = {C070 / C120 / C020 / L101},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
I:(DE-He78)C020-20160331 / I:(DE-He78)L101-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31487678},
doi = {10.6004/jnccn.2019.7287},
url = {https://inrepo02.dkfz.de/record/144745},
}